

## **KMT Hepatech and In Vitro ADMET Laboratories to Offer Human Hepatocytes from Chimeric Mouse**

**Edmonton, March 8, 2017** – KMT Hepatech, Inc. (“KMT”) and In Vitro ADMET Laboratories, LLC (“IVAL”) announced today that they have reached an agreement under which IVAL will prepare freshly isolated or cryopreserved (suspension or plateable grade) human hepatocytes derived from proprietary KMT mouse model - the KMT Mouse™ (uPA/SCID mouse model with stable human hepatocytes engraftment of up to 95 per cent).

“The possibility of generating an almost indefinite supply of human hepatocytes from one donor will increase the availability of an effective in vitro hepatitis B culture system and infection model to supplement our industry leading in vivo hepatitis infection system. Thus, the uPA/SCID mouse model makes additional important contributions to the development of curative therapies in hepatitis,” says Dr. Norman Kneteman, President and CEO of KMT Hepatech.

“We are successful in the isolation and cryopreservation of hepatocytes from KMT animals to retain key hepatic properties. The hepatocytes can be used as an in vitro experimental system to provide information augmenting the research applications of KMT animals,” says Dr. Albert P. Li, President and CEO of IVAL.

Scientists from IVAL and KMT Hepatech representatives will be able to answer questions about newly-formed alliance at the 56<sup>th</sup> Annual Society of Toxicology Meeting and ToxExpo held March 12-16, 2017 in Baltimore, MD, USA. Please visit IVAL at booth #2439 or KMT representatives at booth #2542 for more information about the alliance’s unique product offering.

**About KMT Hepatech, Inc.:** A private company providing in vivo research services utilizing proprietary platform technology of the chimeric mouse model with highly humanized liver (up to 95% of stable human hepatocyte engraftment). Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in infectious diseases (hepatitis B, hepatitis C and malaria), early assessment of human hepatotoxicity and characterization of human-type drug metabolism.

**About IVAL Inc.:** IVAL is privately-owned company specialized in the provision of in vitro experimental reagents and contract research service for drug metabolism, drug-drug interactions, and drug toxicity. The founder of IVAL, Dr. Albert P. Li, is an internationally renowned scientist who pioneered the isolation and cryopreservation of human and animal hepatocytes.

**KMT Contact:**

Dr. Svetlana Sapelnikova

KMT Hepatech, Inc.

+1 (780) 641 1917

[ssapelnikova@kmthepatech.com](mailto:ssapelnikova@kmthepatech.com)

**IVAL Contact:**

Dr. Albert P. Li

In Vitro ADMET Laboratories

+1 (410) 869 9037

[lialbert@invitroadmet.com](mailto:lialbert@invitroadmet.com)